SAN FRANCISCO, Jan. 24, 2011 (GLOBE NEWSWIRE) -- Immunomedics , Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that combining antibody-directed drug and radionuclide therapeutics for pancreatic cancer improved efficacy in preclinical studies with minimal toxicity. Results from these investigations were presented at the 2011 Gastrointestinal Cancers Symposium.
Immunomedics Reports First Experimental Studies Combining Antibody-Drug Conjugate With Antibody-Directed Radiation Therapy For Pancreatic Cancer
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.